RNA binding motif protein Y-linked family 2 member J, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RBMY2JP profile across patient tissues and cancer cell-line models. RBMY2JP expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RBMY2JP is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RBMY2JP RNA expression shows 4,268 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, HNSC, and STAD as cancer lineages where RBMY2JP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY2JP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY2JP survival associations across molecular data types. RBMY2JP RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY2JP RNA expression–survival associations across cancer types. High RBMY2JP expression shows unfavorable associations in THCA, HNSC, ACC and CESC, but favorable associations in LUSC and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RBMY2JP RNA expression.
This table summarizes RBMY2JP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY2JP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY2JP shows higher tumor expression in HNSC, LUSC, COAD, BLCA and LUAD. The HNSC box plot shows higher RBMY2JP RNA expression in tumor versus normal tissue (log2 FC = +0.453, t-test p < 0.001).
This table shows molecular features associated with RBMY2JP in patient tissues and cancer cell lines. In patient samples, RBMY2JP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
